Research programme: DTaP vaccine - Serum Institute of India

Drug Profile

Research programme: DTaP vaccine - Serum Institute of India

Alternative Names: Acellular pertusis vaccines - Serum Institute of India; Diphtheria tetanus-acellular pertussis vaccine - Serum Institute of India

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Serum Institute of India
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diphtheria; Pertussis; Tetanus

Most Recent Events

  • 22 Mar 2017 Serum Institute of India plans a phase I trial for Diphtheria, Pertussis and Tetanus in India (CTRI2017-03-008003)
  • 30 Nov 2016 Genticel has patent protection for GTL 003 in USA
  • 02 Feb 2015 Research programme: DTaP vaccine - Serum Institute of India is available for licensing in (excluding USA, Canada, New Zealand, Australia, Japan, Israel, Turkey, Europe) as of 02 Feb 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top